98 related articles for article (PubMed ID: 19345670)
1. The juxtamembrane domain in ETV6/FLT3 is critical for PIM-1 up-regulation and cell proliferation.
Vu HA; Xinh PT; Kano Y; Tokunaga K; Sato Y
Biochem Biophys Res Commun; 2009 Jun; 383(3):308-13. PubMed ID: 19345670
[TBL] [Abstract][Full Text] [Related]
2. Constitutively activated FLT3 phosphorylates BAD partially through pim-1.
Kim KT; Levis M; Small D
Br J Haematol; 2006 Sep; 134(5):500-9. PubMed ID: 16869825
[TBL] [Abstract][Full Text] [Related]
3. Tel/PDGFRbeta induces stem cell differentiation via the Ras/ERK and STAT5 signaling pathways.
Dobbin E; Graham C; Corrigan PM; Thomas KG; Freeburn RW; Wheadon H
Exp Hematol; 2009 Jan; 37(1):111-121. PubMed ID: 19100521
[TBL] [Abstract][Full Text] [Related]
4. Transformation by oncogenic mutants and ligand-dependent activation of FLT3 wild-type requires the tyrosine residues 589 and 591.
Vempati S; Reindl C; Wolf U; Kern R; Petropoulos K; Naidu VM; Buske C; Hiddemann W; Kohl TM; Spiekermann K
Clin Cancer Res; 2008 Jul; 14(14):4437-45. PubMed ID: 18628457
[TBL] [Abstract][Full Text] [Related]
5. ETV6/FLT3 Fusion Is a Novel Client Protein of Hsp90.
Ly BTK; Chi HT
Oncol Res; 2018 Sep; 26(8):1201-1205. PubMed ID: 29471895
[TBL] [Abstract][Full Text] [Related]
6. FLT3 is fused to ETV6 in a myeloproliferative disorder with hypereosinophilia and a t(12;13)(p13;q12) translocation.
Vu HA; Xinh PT; Masuda M; Motoji T; Toyoda A; Sakaki Y; Tokunaga K; Sato Y
Leukemia; 2006 Aug; 20(8):1414-21. PubMed ID: 16761019
[TBL] [Abstract][Full Text] [Related]
7. Mislocalized activation of oncogenic RTKs switches downstream signaling outcomes.
Choudhary C; Olsen JV; Brandts C; Cox J; Reddy PN; Böhmer FD; Gerke V; Schmidt-Arras DE; Berdel WE; Müller-Tidow C; Mann M; Serve H
Mol Cell; 2009 Oct; 36(2):326-39. PubMed ID: 19854140
[TBL] [Abstract][Full Text] [Related]
8. MS-275, a novel histone deacetylase inhibitor with selectivity against HDAC1, induces degradation of FLT3 via inhibition of chaperone function of heat shock protein 90 in AML cells.
Nishioka C; Ikezoe T; Yang J; Takeuchi S; Koeffler HP; Yokoyama A
Leuk Res; 2008 Sep; 32(9):1382-92. PubMed ID: 18394702
[TBL] [Abstract][Full Text] [Related]
9. ETV6: a versatile player in leukemogenesis.
Bohlander SK
Semin Cancer Biol; 2005 Jun; 15(3):162-74. PubMed ID: 15826831
[TBL] [Abstract][Full Text] [Related]
10. A role of Gab2 association in Flt3 ITD mediated Stat5 phosphorylation and cell survival.
Masson K; Liu T; Khan R; Sun J; Rönnstrand L
Br J Haematol; 2009 Jul; 146(2):193-202. PubMed ID: 19438505
[TBL] [Abstract][Full Text] [Related]
11. Constitutive Fms-like tyrosine kinase 3 activation results in specific changes in gene expression in myeloid leukaemic cells.
Kim KT; Baird K; Davis S; Piloto O; Levis M; Li L; Chen P; Meltzer P; Small D
Br J Haematol; 2007 Sep; 138(5):603-15. PubMed ID: 17686054
[TBL] [Abstract][Full Text] [Related]
12. Pim-1 kinase phosphorylates and stabilizes 130 kDa FLT3 and promotes aberrant STAT5 signaling in acute myeloid leukemia with FLT3 internal tandem duplication.
Natarajan K; Xie Y; Burcu M; Linn DE; Qiu Y; Baer MR
PLoS One; 2013; 8(9):e74653. PubMed ID: 24040307
[TBL] [Abstract][Full Text] [Related]
13. Transformation of Ba/F3 cells and Rat-1 cells by ETV6/ARG.
Iijima Y; Okuda K; Tojo A; Tri NK; Setoyama M; Sakaki Y; Asano S; Tokunaga K; Kruh GD; Sato Y
Oncogene; 2002 Jun; 21(28):4374-83. PubMed ID: 12080468
[TBL] [Abstract][Full Text] [Related]
14. Mutations in the SAM domain of the ETV6-NTRK3 chimeric tyrosine kinase block polymerization and transformation activity.
Tognon CE; Mackereth CD; Somasiri AM; McIntosh LP; Sorensen PH
Mol Cell Biol; 2004 Jun; 24(11):4636-50. PubMed ID: 15143160
[TBL] [Abstract][Full Text] [Related]
15. Multistep pathogenesis of leukemia via the MLL-AF4 chimeric gene/Flt3 gene tyrosine kinase domain (TKD) mutation-related enhancement of S100A6 expression.
Yamaguchi H; Hanawa H; Uchida N; Inamai M; Sawaguchi K; Mitamura Y; Shimada T; Dan K; Inokuchi K
Exp Hematol; 2009 Jun; 37(6):701-14. PubMed ID: 19463771
[TBL] [Abstract][Full Text] [Related]
16. A constitutively active SPTBN1-FLT3 fusion in atypical chronic myeloid leukemia is sensitive to tyrosine kinase inhibitors and immunotherapy.
Grand FH; Iqbal S; Zhang L; Russell NH; Chase A; Cross NC
Exp Hematol; 2007 Nov; 35(11):1723-7. PubMed ID: 17764812
[TBL] [Abstract][Full Text] [Related]
17. ETV6/ARG oncoprotein confers autonomous cell growth by enhancing c-Myc expression via signal transducer and activator of transcription 5 activation in the acute promyelocytic leukemia cell line HT93A.
Iriyama N; Hatta Y; Takei M
Leuk Lymphoma; 2015; 56(8):2416-23. PubMed ID: 25373509
[TBL] [Abstract][Full Text] [Related]
18. Identification of the nuclear localization motif in the ETV6 (TEL) protein.
Park H; Seo Y; Kim JI; Kim WJ; Choe SY
Cancer Genet Cytogenet; 2006 Jun; 167(2):117-21. PubMed ID: 16737910
[TBL] [Abstract][Full Text] [Related]
19. Expression cloning of oligomerization-activated genes with cell-proliferating potency by pseudotype retrovirus vector.
Abe A; Emi N; Kanie T; Imagama S; Kuno Y; Takahashi M; Saito H; Naoe T
Biochem Biophys Res Commun; 2004 Jul; 320(3):920-6. PubMed ID: 15240136
[TBL] [Abstract][Full Text] [Related]
20. ETV6 fusion genes in hematological malignancies: a review.
De Braekeleer E; Douet-Guilbert N; Morel F; Le Bris MJ; Basinko A; De Braekeleer M
Leuk Res; 2012 Aug; 36(8):945-61. PubMed ID: 22578774
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
